Trump MFN Drug Pricing Deals 2026: What 17 Company Agreements Mean for Your Prescriptions

# Trump MFN Drug Pricing Deals 2026: What 17 Company Agreements Mean for Your Prescriptions

> **Quick answer:** On April 23, 2026, Regeneron became the 17th major pharmaceutical company to sign a Most Favored Nation pricing agreement with the Trump administration — completing a deal sweep that now covers 86% of the branded U.S. drug market. Specific savings are real and large: Praluent (cholesterol) dropped from $537 to $225 per month, Ozempic and Wegovy are on track to fall from over $1,000 to as low as $199, and Regeneron's breakthrough hearing-loss gene therapy Otarmeni is being offered at zero cost to eligible U.S. patients. Access runs through TrumpRx.gov as cash-pay coupons — with key limitations patients need to understand before switching.

*This article is for informational purposes only and does not replace professional medical advice. Consult a healthcare provider for medical concerns or before making any changes to your prescription medications.*

Trump's most favored nation drug pricing program quietly became the most significant shift in U.S. prescription drug costs in a generation — and most patients have no idea how it affects their specific medications. The Regeneron deal on April 23, 2026, closed the loop on 17 planned agreements covering 86% of the branded drug market. Here is what the savings actually look like, which drugs are now covered, how TrumpRx works in practice, and the limitations every patient needs to know before switching from insurance to the cash-pay program.

## The Final Deal: Regeneron Closes Out 17 Agreements

The Trump administration's most favored nation drug pricing initiative began with an executive order on May 12, 2025, followed by formal letters to manufacturers on July 31, 2025. The first deal closed on September 30, 2025. By the time Regeneron signed on April 23, 2026, all 17 targeted companies had reached agreements.